Print this article
- 07/28/2017

Proteros enters into new research collaboration with Johnson & Johnson Innovation on sub-class of epigenetic targets

Pharma Horizon

Proteros biostructures GmbH announced that the company has entered into a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, on a sub-class of epigenetic targets. The deal was facilitated by Johnson & Johnson Innovation.

The new collaboration agreement is focused on the discovery of novel lead compounds against several epigenetic targets for various cancer indications. Under the agreement, Janssen gains access to Proteros’ proprietary Nucleosomal Epigenetic Assay Technology (NEATTM) and discovery platform aimed at technically complex targets to identify quality lead compounds. Janssen has the option to license the lead compounds for further development and commercialization or the parties may jointly further develop and partner.

Financial terms of the collaboration were not disclosed.

Dr. Torsten Neuefeind, CEO of Proteros commented: “We are pleased to be working with Janssen to address a set of novel and complex epigenetic targets to create oncology drugs. We believe that the structure of the collaboration will accelerate the discovery of novel therapies and maximize the value generation for both parties.”